MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
CIA-Linked Investor Helped Quantum Systems Expand in US 
OpenAI Rejects Apple Trade Secret Theft Claims 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
France Targets Shein, Temu With Fast-Fashion Fees 
Toyota Global Sales Fall as China Demand Slumps 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Add as a preferred source on Google
DURHAM, N.C., March 28, 2018 -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it will report fourth quarter and year-end 2017 financial results and operational highlights prior to the market open on Monday, April 2, 2018.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, Rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Funding for the development of AGS-004 has been provided by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Collaboratory of Research for AIDS Eradication.
Investor Contact:
Richard Katz, MD, MBA
Chief Financial Officer
Argos Therapeutics, Inc.
919-287-6315
[email protected]
Media Contact:
Adam Daley
Berry & Company Public Relations
212.253.8881
[email protected]
